National Organization for Rare Disorders (NORD) 2021
Efficacy and Safety of Pegcetacoplan at 48 Weeks in Patients with Paroxysmal Nocturnal Hemoglobinuria (PEGASUS Phase 3)
Landing
Back to Conference Resources
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.